# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: K180264   
B. Purpose for Submission: To obtain a substantial equivalence determination and FDA clearance for a new device.   
C. Measurand: Anti-Borrelia burgdorferi (IgM and IgG) antibodies   
D. Type of Test: Enzyme Immunoassay   
E. Applicant: Gold Standard Diagnostics   
F. Proprietary and Established Names: Gold Standard Diagnostics Borrelia burgdorferi IgG/IgM ELISA Test Kit

# G. Regulatory Information:

1. Regulation section: 21 CFR 866.3830; Treponema pallidum treponemal test reagents.

2. Classification: Class II

3. Product code: LSR; Reagent, Borrelia Serological Reagent

4. Panel: Microbiology

# H. Intended Use:

1. Intended use(s): The Gold Standard Diagnostics Borrelia burgdorferi IgG/IgM ELISA Test Kit is intended as a qualitative presumptive (first-step) test for the detection of IgG and IgM antibodies to $B .$ . burgdorferi sensu stricto in human serum from symptomatic patients or people suspected of infection. Positive and equivocal results must be supplemented by testing with a second-step Western blot assay.

2. Indication(s) for use: Same as Intended Use

3. Special conditions for use statement(s): For prescription use only.

4. Special instrument requirements: N/A

I. Device Description: The Gold Standard Diagnostics Borrelia burgdorferi $\mathrm { I g G / I g M }$ test consists of antigenic proteins specific for B. burgdorferi (sensu stricto) which are either purified or cloned and expressed in the surrogate host E.coli. The individual antigens are transferred to polystyrene 96 well microtiter plates.

During the test procedure, antibodies to $B$ . burgdorferi (sensu stricto) if present in the human serum sample will bind to the antigens coated onto the wells forming antigen-antibody complexes. Excess antibodies are removed by washing. A conjugate of goat anti-human $\mathrm { I g G / I g M }$ antibodies conjugated with horseradish peroxidase are then added, which binds to the antigen-antibody complexes. Excess conjugate is removed by washing. This is followed by the addition of a chromogenic substrate, tetramethylbenzidine (TMB). If specific antibodies to the antigen are present in the patients’ serum, a blue color will develop. The enzymatic reaction is then stopped with a stopping solution causing the contents of the well to turn yellow. The wells are read photometrically with a microplate reader at $4 5 0 \mathrm { n m }$ .

# J. Substantial Equivalence Information:

1. Predicate device name(s): Trinity Biotech Captia Borrelia burgdorferi IgG/IgM ELISA Test Kit.

2. Predicate 510(k) number(s): K033070

3. Comparison with predicate:

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate(K033070)</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">The Gold StandardDiagnostics Borreliaburgdorferi IgG/IgMELISA Test Kit is intendedas a qualitative presumptive(first-step) test for thedetection of IgG and IgMantibodies to B. burgdorferisensu stricto in humanserum from symptomaticpatients or people suspectedof infection. Positive andequivocal results must besupplemented by testingwith a second-step Westernblot assay.</td><td colspan="1" rowspan="1">Trinity Biotech CaptiaBorrelia burgdorferiIgG/IgM ELISA TestKit is intended for thequalitative presumptive(first-step) detection oftotal (IgG/IgM) antibodiesto B. burgdorferi in humanserum. This ELISA shouldonly be used for patientswith signs and symptomsthat are consistent withLyme disease. Equivocal orpositive results must besupplemented by testingwith a standardizedWestern blot (second step)procedure. Positivesupplemental (second-step)results are supportiveevidence of exposure to B.burgdorferi and can beused to support a clinicaldiagnosis of Lyme disease.The diagnosis of Lyme</td></tr><tr><td colspan="1" rowspan="1">−</td><td colspan="1" rowspan="1">−</td><td colspan="1" rowspan="1">disease must be madebased on history, signs(such as erythemamigrans), symptoms, andother laboratory data, inaddition to the presence ofantibodies to B.burgdorferi. Negativeresults (either first orsecond step) should not beused to exclude Lymedisease.</td></tr><tr><td colspan="1" rowspan="1">Assay Format</td><td colspan="1" rowspan="1">Antigen coated microtiterplate - 96 wells.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Technology</td><td colspan="1" rowspan="1">ELISA</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Matrix</td><td colspan="1" rowspan="1">Human serum</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Controls Provided</td><td colspan="1" rowspan="1">Positive,, Cut-off, Negative</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagents Provided</td><td colspan="1" rowspan="1">Diluent, Wash, Conjugate,Substrate, Stop Solution</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reported Results</td><td colspan="1" rowspan="1">Positive, Equivocal,Negative</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Interpretation</td><td colspan="1" rowspan="1">Optical density readingsfrom Spectrophotometer</td><td colspan="1" rowspan="1">Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Sample Processing</td><td rowspan=1 colspan=1>Dilute Samples 1:100 inDiluent</td><td rowspan=1 colspan=1>Dilute Samples 1:20 inDiluent</td></tr><tr><td rowspan=1 colspan=1>Volumes</td><td rowspan=1 colspan=1>100ul sample, 50ulsubstrate, 50ul stop solution</td><td rowspan=1 colspan=1>100ul sample, 100ulsubstrate, 100ul stopsolution</td></tr><tr><td rowspan=1 colspan=1>Incubation</td><td rowspan=1 colspan=1>15/15/15 minutes at roomtemperature</td><td rowspan=1 colspan=1>25/25/10-15 minutes atroom temperature</td></tr><tr><td rowspan=1 colspan=1>Antigens</td><td rowspan=1 colspan=1>B. burgdorferi B31 strain,B. burgdorferi 2591 strain,B. burgdorferi recombinantVlsE, B31 strain</td><td rowspan=1 colspan=1>B. burgdorferi B31 strain</td></tr><tr><td rowspan=1 colspan=1>Results Interpretation</td><td rowspan=1 colspan=1>Convert to units.Negative: &lt;9Equivocal: 9.0-11.0Positive: &gt;11.0</td><td rowspan=1 colspan=1>Convert to units.Negative: ≤0.90Equivocal: 0.91-1.09Positive: ≥1.10</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable): N/A

L. Test Principle: Enzyme Immunoassay

M. Performance Characteristics (if/when applicable):

1. Analytical performance: a. Precision/Reproducibility:

Precision: To determine the precision of the Gold Standard Diagnostics Borrelia burgdorferi $\mathrm { I g G / I g M }$ ELISA Test, a within-lab precision study was conducted. A precision panel consisting of a negative sample, a high negative sample, a low positive sample, and a moderate positive sample, along with the kit controls, was tested in-house. The sample panel was masked and randomized. Each of the panel members was tested in duplicate, twice per day, for 12 days. The results are summarized in the following table.

Table 1: Precision Study   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>MeanUnits</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Wthin-Run</td><td rowspan=1 colspan=1>Between-Run</td><td rowspan=1 colspan=1>Between-Day</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>MbderatePositive</td><td rowspan=2 colspan=1>48</td><td rowspan=2 colspan=1>19.6</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.815</td><td rowspan=1 colspan=1>1.534</td><td rowspan=1 colspan=1>1.472</td><td rowspan=1 colspan=1>1.737</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>4.2%</td><td rowspan=1 colspan=1>7.8%</td><td rowspan=1 colspan=1>7.5%</td><td rowspan=1 colspan=1>8.9%</td></tr><tr><td rowspan=2 colspan=1>LowPositive</td><td rowspan=2 colspan=1>48</td><td rowspan=2 colspan=1>12.1</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.267</td><td rowspan=1 colspan=1>1.417</td><td rowspan=1 colspan=1>1.248</td><td rowspan=1 colspan=1>1.442</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>11.7%</td><td rowspan=1 colspan=1>10.3%</td><td rowspan=1 colspan=1>11.9%</td></tr><tr><td rowspan=2 colspan=1>HighNegative</td><td rowspan=2 colspan=1>48</td><td rowspan=2 colspan=1>6.1</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.211</td><td rowspan=1 colspan=1>0.662</td><td rowspan=1 colspan=1>0.642</td><td rowspan=1 colspan=1>0.695</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>10.8%</td><td rowspan=1 colspan=1>10.5%</td><td rowspan=1 colspan=1>11.4%</td></tr><tr><td rowspan=2 colspan=1>Negative</td><td rowspan=2 colspan=1>48</td><td rowspan=2 colspan=1>1.7</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.113</td><td rowspan=1 colspan=1>0.164</td><td rowspan=1 colspan=1>0.151</td><td rowspan=1 colspan=1>0.199</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>6.6%</td><td rowspan=1 colspan=1>9.6%</td><td rowspan=1 colspan=1>8.8%</td><td rowspan=1 colspan=1>11.6%</td></tr></table>

Reproducibility: A reproducibility panel consisting of a negative sample, a high negative sample, a low positive sample, and a moderate positive sample, along with the kit controls, was tested at three different sites. The sample panel was masked and randomized. Each of the panel members was tested in triplicate, twice per day, for five days. The Within-Run, Between-Run, Between-Days, and Between-Sites Standard Deviation and Coefficients of Variation (CV) were calculated. The results are summarized in the following table.

Table 2: Reproducibility Study   

<table><tr><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">MeanUhits</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Wthin-Run</td><td colspan="1" rowspan="1">Between-Run</td><td colspan="1" rowspan="1">Between-Day</td><td colspan="1" rowspan="1">BetweenSites</td><td colspan="1" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="2">ModeratePositive</td><td colspan="1" rowspan="2">90</td><td colspan="1" rowspan="2">21.1</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">1.117</td><td colspan="1" rowspan="1">1.543</td><td colspan="1" rowspan="1">1.434</td><td colspan="1" rowspan="1">0.386</td><td colspan="1" rowspan="1">1.905</td></tr><tr><td colspan="1" rowspan="1">CV</td><td colspan="1" rowspan="1">5.3%</td><td colspan="1" rowspan="1">7.3%</td><td colspan="1" rowspan="1">6.8%</td><td colspan="1" rowspan="1">1.8%</td><td colspan="1" rowspan="1">9.0%</td></tr><tr><td colspan="1" rowspan="2">LowPositive</td><td colspan="1" rowspan="2">90</td><td colspan="1" rowspan="2">13.8</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">0.591</td><td colspan="1" rowspan="1">1.155</td><td colspan="1" rowspan="1">1.026</td><td colspan="1" rowspan="1">0.404</td><td colspan="1" rowspan="1">1.297</td></tr><tr><td colspan="1" rowspan="1">CV</td><td colspan="1" rowspan="1">4.3%</td><td colspan="1" rowspan="1">8.4%</td><td colspan="1" rowspan="1">7.5%</td><td colspan="1" rowspan="1">29%</td><td colspan="1" rowspan="1">9.4%</td></tr><tr><td colspan="1" rowspan="2">HighNegative</td><td colspan="1" rowspan="2">90</td><td colspan="1" rowspan="2">6.4</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">0.323</td><td colspan="1" rowspan="1">0.756</td><td colspan="1" rowspan="1">0.715</td><td colspan="1" rowspan="1">0.237</td><td colspan="1" rowspan="1">0.822</td></tr><tr><td colspan="1" rowspan="1">CV</td><td colspan="1" rowspan="1">5.0%</td><td colspan="1" rowspan="1">11.7%</td><td colspan="1" rowspan="1">11.1%</td><td colspan="1" rowspan="1">3.7%</td><td colspan="1" rowspan="1">12.8%</td></tr><tr><td colspan="1" rowspan="2">Negative</td><td colspan="1" rowspan="2">90</td><td colspan="1" rowspan="2">1.6</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">0.145</td><td colspan="1" rowspan="1">0.335</td><td colspan="1" rowspan="1">0.312</td><td colspan="1" rowspan="1">0.347</td><td colspan="1" rowspan="1">0.365</td></tr><tr><td colspan="1" rowspan="1">CV</td><td colspan="1" rowspan="1">9.1%</td><td colspan="1" rowspan="1">21.1%</td><td colspan="1" rowspan="1">19.6%</td><td colspan="1" rowspan="1">21.8%</td><td colspan="1" rowspan="1">23.0%</td></tr></table>

b. Linearity/assay reportable range: N/A c. Traceability, Stability, Expected values (controls, calibrators, or methods): N/A

d. Detection limit: N/A e. Analytical specificity:

Analytical Specificity: The analytical specificity was determined by testing 210 asymptomatic individuals’ samples from endemic (Pennsylvania) and non-endemic (Arizona) regions. The Gold Standard Diagnostics Borrelia burgdorferi lgG/IgM ELISA Test results are summarized in the following table.

Table 3: Analytical Specificity Study   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Number ofSamples</td><td rowspan=1 colspan=1>NmberPositive/Equivocal</td><td rowspan=1 colspan=1>AnalyticalSpecificity</td></tr><tr><td rowspan=1 colspan=1>Endemic Region</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>97.3%</td></tr><tr><td rowspan=1 colspan=1>Non-endemic Region</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>98.0%</td></tr></table>

Cross Reactivity: A study using 221 samples was conducted to evaluate potential cross reactivity from different disease conditions. The samples were obtained from serum vendors who confirmed their positivity for each respective marker. The samples were tested on the Gold Standard Diagnostics Borrelia burgdorferi $\mathrm { I g G / I g M }$ ELISA Test. The results are summarized in the following table.

Table 4: Cross-Reactivity Study   

<table><tr><td colspan="1" rowspan="1">Infection / Diagnosis</td><td colspan="1" rowspan="1">Number of SeraTested</td><td colspan="1" rowspan="1"># Positive / (%)</td></tr><tr><td colspan="1" rowspan="1">Tick-borne Relapsing Fever</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">2 / (7.7%)</td></tr><tr><td colspan="1" rowspan="1">Treponemal Infections</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">2* / (8.7%)</td></tr><tr><td colspan="1" rowspan="1">Rickettsia</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0 / (0%)</td></tr><tr><td colspan="1" rowspan="1">Ehrlichiosis</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0 / (0%)</td></tr><tr><td colspan="1" rowspan="1">Babesiosis</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">0 /(0%)</td></tr><tr><td colspan="1" rowspan="1">Leptospirosis</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">0 / (0%)</td></tr><tr><td colspan="1" rowspan="1">Parvovirus B19</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">0 / (0%)</td></tr><tr><td colspan="1" rowspan="1">Influenza A&amp;B</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0 / (0%)</td></tr><tr><td colspan="1" rowspan="1">Epstein-Barr Virus</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0 / (0%)</td></tr><tr><td colspan="1" rowspan="1">Cytomegalovirus</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">0 / (0%)</td></tr><tr><td colspan="1" rowspan="1">H. pylori</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">0 / (0%)</td></tr><tr><td colspan="1" rowspan="1">Fibromyalgia</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">1/ (10%)</td></tr><tr><td colspan="1" rowspan="1">Rheumatoid Arthritis</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">0 / (0%)</td></tr><tr><td colspan="1" rowspan="1">Herpes Simplex Virus</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">0 / (0%)</td></tr><tr><td colspan="1" rowspan="1">Varicella ZosterVirus</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">0 /(0%)</td></tr><tr><td colspan="1" rowspan="1">Autoimmune Disease</td><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">0 / (0%)</td></tr></table>

\*Also positive on the predicate device

Interfering Substances: The effect of potential interfering substances on samples using the Gold Standard Diagnostics Borrelia burgdorferi $\mathrm { I g G / I g M }$ ELISA Test was evaluated. Three samples, a negative, a low positive, and a moderate positive were spiked with high levels of interferants and were tested along with serum without spiked interferants. The recommended concentrations from the guideline “Interference Testing in Clinical Chemistry EP7-A2” from the Clinical and Laboratory Standards Institute were used. The tested substances did not affect the performance of the Gold Standard Diagnostics Borrelia burgdorferi $\mathrm { I g G / I g M }$ ELISA Test.

Table 5: Interfering Substances Study   

<table><tr><td rowspan=1 colspan=1>Substance</td><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>Interference</td></tr><tr><td rowspan=1 colspan=1>Albumin</td><td rowspan=1 colspan=1>120 g/L</td><td rowspan=1 colspan=1>None detected</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>342 μmol/L</td><td rowspan=1 colspan=1>None detected</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>13 mmol/L</td><td rowspan=1 colspan=1>Nonedetected</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>2 g/L</td><td rowspan=1 colspan=1>Nonedetected</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>37 mmol/L</td><td rowspan=1 colspan=1>None detected</td></tr></table>

f. Assay cut-off:

Determination of the Assay Cut-off: The cut-off was determined by testing a total of 200 normal sera which consisted of 100 sera from an endemic region of Lyme disease and 100 sera from a non-endemic region. The mean plus two standard deviations was used to determine the assay cut-off. After the cut-off was determined 125 characterized Lyme disease samples were tested. An ROC analysis was then generated with the 325 samples (200 normal and 125 characterized samples) to verify the chosen cut-off. The analysis confirmed that the assay cut-off provided an optimal level of sensitivity and specificity.

# 2. Comparison studies:

# a. Method comparison with predicate device:

Comparison with Predicate Device: Comparison studies were conducted at three sites (one internal and two external reference laboratories) using prospective samples submitted for Lyme serology testing. Five hundred and twenty (520) serum samples were tested on both the Gold Standard Diagnostics Borrelia burgdorferi $\mathrm { I g G / I g M }$ ELISA Test and on the predicate $B .$ . burgdorferi IgG/IgM ELISA Test. The results are summarized in the following table.

Table 6: Percent Agreement with Predicate Device   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Predicate IgG/IgM ELISA</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal*</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>Gold StandardDiagnostics Borreliaburgdorferi IgG/IgMELISA Test Kit</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>55</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>64</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>19</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>434</td><td rowspan=1 colspan=1>437</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>445</td><td rowspan=1 colspan=1>520</td></tr></table>

\*Equivocal samples counted as positive

Positive percent agreement $= 9 6 . 0 \%$ (72/75) $9 5 \%$ C I $8 8 . 8 \% - 9 9 . 2 \% )$ Negative percent agreement $= 9 7 . 5 \%$ (434/445) $9 5 \%$ C I $9 5 . 6 \% - 9 8 . 8 \% )$

b. Matrix comparison: N/A

3. Clinical studies:

a. Clinical Sensitivity:

Sensitivity Study: A sensitivity study was performed on 89 clinically characterized samples. The samples encompass early, disseminated, and late stages of Lyme disease. The samples were tested on both the Gold Standard Diagnostics Borrelia burgdorferi $\mathrm { I g G / I g M }$ ELISA Test and on the predicate $B .$ . burgdorferi IgG/IgM ELISA Test. The results are summarized in the following table.

Table 7: Case Confirmed Lyme Disease Samples   

<table><tr><td rowspan=1 colspan=1>DiseaseStage</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Gold StandardDiagnostics Borreliaburgdorferi IgG/IgMELISATest Kit</td><td rowspan=1 colspan=1>Predicate IgG/IgMELISA</td></tr><tr><td rowspan=1 colspan=1>Early</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>76.3%(29/38)</td><td rowspan=1 colspan=1>78.9%(30/38)</td></tr><tr><td rowspan=1 colspan=1>Disseminated</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>100.0%(15/15)</td><td rowspan=1 colspan=1>100.0%(15/15)</td></tr><tr><td rowspan=1 colspan=1>Late</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>97.2%(35/36)</td><td rowspan=1 colspan=1>94.4%(34/36)</td></tr></table>

CDC Panel: A standard panel of positive and negative specimens provided by the Center of Disease Control (CDC) for Lyme disease detection was tested on both the Gold Standard Diagnostics Borrelia burgdorferi $\mathrm { I g G / I g M }$ ELISA Test and on the predicate device. The results are summarized in the following table.

Table 8: Testing of CDC Lyme Disease Panel   

<table><tr><td rowspan=2 colspan=1>DiseaseStage</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=2>Gold Standard DiagnosticsBorrelia burgdorferiIgG/IgM ELISA Test Kit</td><td rowspan=1 colspan=2>Predicate IgG/IgM ELISA</td></tr><tr><td rowspan=1 colspan=1>PositiveorEquivocal</td><td rowspan=1 colspan=1>% Agreementwith ClinicalDiagnosis</td><td rowspan=1 colspan=1>PositiveorEquivocal</td><td rowspan=1 colspan=1>% Agreementwith ClinicalDiagnosis</td></tr><tr><td rowspan=1 colspan=1>Healthy</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Early(0-2 months)</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>86.7%</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>80.0%</td></tr><tr><td rowspan=1 colspan=1>Convalescent(3-12 months)</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>53.8%</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>53.8%</td></tr><tr><td rowspan=1 colspan=1>Late(&gt;1 year)</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>100%</td></tr></table>

b. Clinical specificity: N/A

c. Other clinical supportive data (when a. and b. are not applicable): N/A

4. Clinical cut-off: N/A

5. Expected values/Reference range:

The range of values and positivity rate among different studies and populations for the Gold Standard Diagnostics Borrelia burgdorferi IgG/IgM ELISA Test are as follows.

Table 9: Expected Values   

<table><tr><td rowspan=2 colspan=1>Population</td><td rowspan=2 colspan=1>#Samples</td><td rowspan=1 colspan=3>Unit Results</td><td rowspan=1 colspan=2>Qualitative Results</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>Std. Dev.</td><td rowspan=1 colspan=1>#Positive/Equivocal</td><td rowspan=1 colspan=1>%Positive/Equivocal</td></tr><tr><td rowspan=1 colspan=1>Normal Endemic</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>06.- 11.3</td><td rowspan=1 colspan=1>2.075</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2.7%</td></tr><tr><td rowspan=1 colspan=1>NormalNon-Endemic</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>0.9- 12.3</td><td rowspan=1 colspan=1>2.077</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2.0%</td></tr><tr><td rowspan=1 colspan=1>Prospective Study</td><td rowspan=1 colspan=1>520</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>0.70-32.3</td><td rowspan=1 colspan=1>5.407</td><td rowspan=1 colspan=1>83</td><td rowspan=1 colspan=1>16.0%</td></tr><tr><td rowspan=1 colspan=1>Sensitivity Study</td><td rowspan=1 colspan=1>89</td><td rowspan=1 colspan=1>25.0</td><td rowspan=1 colspan=1>3.6-34.9</td><td rowspan=1 colspan=1>8.449</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>88.8%</td></tr></table>

Note: It is recommended that each laboratory determine its own normal range based on the population.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809, as applicable.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.